KURA - Kura Oncology Stock Price, News & Analysis

$15.90 0.60 (3.92 %)
(As of 11/23/2017 04:43 AM ET)
Previous Close$15.30
Today's Range$15.31 - $16.30
52-Week Range$4.72 - $16.75
Volume266,900 shs
Average Volume289,490 shs
Market Capitalization$462.30 million
P/E RatioN/A
Dividend YieldN/A
Beta4.92

About Kura Oncology (NASDAQ:KURA)

Kura Oncology logoKura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KURA
CUSIPN/A

Debt

Debt-to-Equity Ratio0.07%
Current Ratio13.48%
Quick Ratio13.48%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.95 per share
Price / Book5.39

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.55)
Net Income$-27,560,000.00
Net MarginsN/A
Return on Equity-53.40%
Return on Assets-44.08%

Miscellaneous

Employees25
Outstanding Shares30,220,000

Frequently Asked Questions for Kura Oncology (NASDAQ:KURA)

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) posted its earnings results on Tuesday, November, 7th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.01. View Kura Oncology's Earnings History.

Where is Kura Oncology's stock going? Where will Kura Oncology's stock price be in 2017?

5 brokerages have issued 1 year target prices for Kura Oncology's shares. Their forecasts range from $16.00 to $19.00. On average, they expect Kura Oncology's stock price to reach $17.75 in the next year. View Analyst Ratings for Kura Oncology.

What are Wall Street analysts saying about Kura Oncology stock?

Here are some recent quotes from research analysts about Kura Oncology stock:

  • 1. Cann analysts commented, "Loss per share was $0.38, compared to our estimated loss of $0.49. This was the result of lower than estimated operating expenses of $9.5 million compared to our estimate of $9.9 million, which resulted in a net loss 4.2% lower than we estimated; and 23% more shares outstanding from an equity offering in the quarter. There were no other remarkable variances in the quarter. Our outlook for 2017-2022 is being adjusted for higher shares outstanding. Our net income estimates for 2018-2022 remain basically unchanged. We are increasing our estimated shares outstanding by approximately 23% in each of these years. We have adjusted our 2017 outlook to reflect the higher shares outstanding and slightly lower estimated operating expense." (11/8/2017)
  • 2. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (10/18/2017)

Are investors shorting Kura Oncology?

Kura Oncology saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,004,902 shares, an increase of 36.6% from the October 13th total of 1,467,694 shares. Based on an average daily volume of 423,794 shares, the short-interest ratio is currently 4.7 days. Currently, 9.3% of the shares of the company are short sold.

Who are some of Kura Oncology's key competitors?

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the folowing people:

  • Troy E. Wilson Ph.D. J.D., Chairman of the Board, President, Chief Executive Officer (Age 48)
  • Heidi Henson CPA, Chief Financial Officer, Secretary (Age 50)
  • Annette North, Senior Vice President, General Counsel (Age 49)
  • Pingda Ren Ph.D., Senior Vice President - Chemistry and Pharmaceutical Sciences (Age 46)
  • Liu Yi Ph.D., Chief Scientific Officer (Age 47)
  • Antonio Gualberto M.D. Ph.D., Chief Medical Officer (Age 50)
  • Steven H. Stein M.D., Director (Age 50)
  • Faheem Hasnain, Independent Director (Age 58)
  • Robert E. Hoffman, Independent Director (Age 51)
  • Thomas R. Malley, Independent Director (Age 47)

Who owns Kura Oncology stock?

Kura Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.95%), EAM Investors LLC (0.70%), Alethea Capital Management LLC (0.56%), Artal Group S.A. (0.36%), Iguana Healthcare Management LLC (0.30%) and Bank of New York Mellon Corp (0.21%). View Institutional Ownership Trends for Kura Oncology.

Who bought Kura Oncology stock? Who is buying Kura Oncology stock?

Kura Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., EAM Investors LLC, Artal Group S.A., Iguana Healthcare Management LLC, JPMorgan Chase & Co., Bank of New York Mellon Corp, Nationwide Fund Advisors and Alethea Capital Management LLC. View Insider Buying and Selling for Kura Oncology.

How do I buy Kura Oncology stock?

Shares of Kura Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kura Oncology's stock price today?

One share of Kura Oncology stock can currently be purchased for approximately $15.90.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $462.30 million. The company earns $-27,560,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Kura Oncology employs 25 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]


MarketBeat Community Rating for Kura Oncology (KURA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Kura Oncology (NASDAQ:KURA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.75 (11.64% upside)

Consensus Price Target History for Kura Oncology (NASDAQ:KURA)

Price Target History for Kura Oncology (NASDAQ:KURA)

Analysts' Ratings History for Kura Oncology (NASDAQ:KURA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$18.00N/AView Rating Details
11/9/2017Citigroup Inc.Boost Price TargetBuy$15.00 -> $19.00N/AView Rating Details
11/8/2017CannReiterated RatingBuyN/AView Rating Details
9/7/2017Cowen and CompanyInitiated CoverageOutperformMediumView Rating Details
8/10/2017Leerink SwannReiterated RatingOutperform$16.00 -> $18.00HighView Rating Details
1/22/2016JMP SecuritiesInitiated CoverageOutperform$24.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Kura Oncology (NASDAQ:KURA)

Earnings by Quarter for Kura Oncology (NASDAQ:KURA)

Earnings History by Quarter for Kura Oncology (NASDAQ KURA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.37)($0.38)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.43)($0.40)ViewListenView Earnings Details
5/15/2017Q1 2017($0.44)($0.39)ViewN/AView Earnings Details
3/14/2017Q4 2016($0.41)($0.38)ViewN/AView Earnings Details
11/7/2016Q3($0.41)($0.37)ViewListenView Earnings Details
8/10/2016Q2($0.34)($0.36)ViewListenView Earnings Details
5/11/2016Q1($0.35)($0.36)ViewN/AView Earnings Details
3/17/2016Q4($0.44)($0.42)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kura Oncology (NASDAQ:KURA)
2017 EPS Consensus Estimate: ($1.63)
2018 EPS Consensus Estimate: ($2.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.50)($0.42)($0.46)
Q2 20172($0.43)($0.42)($0.43)
Q3 20172($0.49)($0.32)($0.41)
Q4 20172($0.36)($0.32)($0.34)
Q1 20181($0.48)($0.48)($0.48)
Q2 20181($0.49)($0.49)($0.49)
Q3 20181($0.63)($0.63)($0.63)
Q4 20181($0.59)($0.59)($0.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kura Oncology (NASDAQ:KURA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kura Oncology (NASDAQ KURA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Kura Oncology (NASDAQ KURA)

Source:
DateHeadline
-$0.34 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter-$0.34 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter
www.americanbankingnews.com - November 22 at 7:10 PM
Oppenheimer Holdings, Inc. Reiterates "$18.00" Price Target for Kura Oncology, Inc. (KURA)Oppenheimer Holdings, Inc. Reiterates "$18.00" Price Target for Kura Oncology, Inc. (KURA)
www.americanbankingnews.com - November 18 at 1:38 PM
Kura Oncology, Inc. (KURA) Receives Consensus Recommendation of "Buy" from AnalystsKura Oncology, Inc. (KURA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 15 at 1:46 AM
Short Interest in Kura Oncology, Inc. (KURA) Rises By 36.6%Short Interest in Kura Oncology, Inc. (KURA) Rises By 36.6%
www.americanbankingnews.com - November 13 at 3:34 AM
BRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and CoBRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and Co
www.reuters.com - November 11 at 3:49 PM
Kura Oncology to Host Investor Day on November 16, 2017Kura Oncology to Host Investor Day on November 16, 2017
finance.yahoo.com - November 11 at 3:49 PM
Leerink Swann Weighs in on Kura Oncology, Inc.s FY2017 Earnings (KURA)Leerink Swann Weighs in on Kura Oncology, Inc.'s FY2017 Earnings (KURA)
www.americanbankingnews.com - November 10 at 2:42 PM
Kura Oncology, Inc. (KURA) to Post FY2017 Earnings of ($1.52) Per Share, Oppenheimer Holdings ForecastsKura Oncology, Inc. (KURA) to Post FY2017 Earnings of ($1.52) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - November 10 at 2:34 PM
Kura Oncology, Inc. (KURA) Releases  Earnings Results, Misses Estimates By $0.01 EPSKura Oncology, Inc. (KURA) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - November 8 at 4:44 PM
Kura Oncologys (KURA) "Buy" Rating Reiterated at CannKura Oncology's (KURA) "Buy" Rating Reiterated at Cann
www.americanbankingnews.com - November 8 at 9:50 AM
 Analysts Expect Kura Oncology, Inc. (KURA) to Post -$0.37 EPS Analysts Expect Kura Oncology, Inc. (KURA) to Post -$0.37 EPS
www.americanbankingnews.com - November 3 at 1:38 PM
Technical Snapshots for These Biotech Stocks -- Kura Oncology, Progenics ...Technical Snapshots for These Biotech Stocks -- Kura Oncology, Progenics ...
www.prnewswire.com - November 3 at 1:32 PM
Technical Snapshots for These Biotech Stocks -- Kura Oncology, Progenics Pharma, Regeneron Pharma, and Seattle GeneticsTechnical Snapshots for These Biotech Stocks -- Kura Oncology, Progenics Pharma, Regeneron Pharma, and Seattle Genetics
www.bizjournals.com - November 3 at 1:32 PM
Kura Oncology to Report Third Quarter 2017 Financial ResultsKura Oncology to Report Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 5:06 AM
Oppenheimer Holdings Comments on Kura Oncology, Inc.s Q1 2018 Earnings (KURA)Oppenheimer Holdings Comments on Kura Oncology, Inc.'s Q1 2018 Earnings (KURA)
www.americanbankingnews.com - October 31 at 11:42 AM
Kura Oncology, Inc. (KURA) to Release Quarterly Earnings on MondayKura Oncology, Inc. (KURA) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 1:50 PM
Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AMLKura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML
finance.yahoo.com - October 29 at 6:02 AM
Kura Oncology (KURA) Says Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC UpdateKura Oncology (KURA) Says Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
www.streetinsider.com - October 28 at 7:34 AM
Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC UpdateKura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
finance.yahoo.com - October 28 at 7:34 AM
Kura Oncology, Inc. (KURA) Given Average Recommendation of "Buy" by AnalystsKura Oncology, Inc. (KURA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 21 at 2:42 AM
Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head andKura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and
www.nasdaq.com - October 17 at 12:55 AM
Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International ConferenceKura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
finance.yahoo.com - October 16 at 7:52 PM
Kura Oncology, Inc. (KURA) Expected to Announce Earnings of -$0.37 Per ShareKura Oncology, Inc. (KURA) Expected to Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - October 15 at 2:06 AM
Zacks.com featured highlights include Build-A-Bear Workshop, Kura Oncology, Norsk Hydro, Schnitzer Steel Industries and SYNNEXZacks.com featured highlights include Build-A-Bear Workshop, Kura Oncology, Norsk Hydro, Schnitzer Steel Industries and SYNNEX
finance.yahoo.com - October 5 at 7:37 AM
Short Interest in Kura Oncology, Inc. (KURA) Increases By 58.9%Short Interest in Kura Oncology, Inc. (KURA) Increases By 58.9%
www.americanbankingnews.com - September 29 at 1:56 AM
Kura Oncology, Inc. (KURA) Receives Average Rating of "Buy" from AnalystsKura Oncology, Inc. (KURA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 26 at 2:44 AM
Is It Time To Buy Kura Oncology Inc (KURA)?Is It Time To Buy Kura Oncology Inc (KURA)?
finance.yahoo.com - September 21 at 9:27 AM
Keep An Eye On These Biotech Stocks This Month, If InvestedKeep An Eye On These Biotech Stocks This Month, If Invested
www.rttnews.com - September 18 at 5:22 AM
Kura Oncology, Inc. (KURA) Short Interest UpdateKura Oncology, Inc. (KURA) Short Interest Update
www.americanbankingnews.com - September 17 at 1:20 AM
3 Reasons Momentum Stock Investors Will Love Kura Oncology (KURA)3 Reasons Momentum Stock Investors Will Love Kura Oncology (KURA)
finance.yahoo.com - September 13 at 4:22 AM
Kura Oncology, Inc. (KURA) Research Coverage Started at Cowen and CompanyKura Oncology, Inc. (KURA) Research Coverage Started at Cowen and Company
www.americanbankingnews.com - September 10 at 9:54 AM
Kura Oncology Inc. (KURA) Is Up Sharply On Phase 2 Study ResultsKura Oncology Inc. (KURA) Is Up Sharply On Phase 2 Study Results
www.nasdaq.com - September 10 at 12:50 AM
Stocks to Watch: Equifax, Pfizer, Kroger, Southwest, Kura Oncology, American Outdoor BrandsStocks to Watch: Equifax, Pfizer, Kroger, Southwest, Kura Oncology, American Outdoor Brands
finance.yahoo.com - September 9 at 3:41 AM
After-Hours Movers 09/07: (KURA) (ZUMZ) (RDFN) Higher; (AOBC) (FNSR) (EFX) Lower (more...)After-Hours Movers 09/07: (KURA) (ZUMZ) (RDFN) Higher; (AOBC) (FNSR) (EFX) Lower (more...)
www.streetinsider.com - September 8 at 5:31 AM
Kura Oncology Inc. (KURA) Is Climbing On Phase 2 Study ResultsKura Oncology Inc. (KURA) Is Climbing On Phase 2 Study Results
www.rttnews.com - September 8 at 5:31 AM
Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck CancerKura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
finance.yahoo.com - September 8 at 12:29 AM
 Analysts Anticipate Kura Oncology, Inc. (KURA) Will Post Earnings of -$0.41 Per Share Analysts Anticipate Kura Oncology, Inc. (KURA) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - September 2 at 2:14 PM
Kura Oncology, Inc. (KURA) Given Consensus Rating of "Buy" by AnalystsKura Oncology, Inc. (KURA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 1 at 10:34 PM
Kura Oncology to Participate in Citi’s 12th Annual Biotech ConferenceKura Oncology to Participate in Citi’s 12th Annual Biotech Conference
finance.yahoo.com - August 29 at 3:32 PM
Q3 2017 Earnings Forecast for Kura Oncology, Inc. (KURA) Issued By Leerink SwannQ3 2017 Earnings Forecast for Kura Oncology, Inc. (KURA) Issued By Leerink Swann
www.americanbankingnews.com - August 18 at 6:42 AM
Reviewing Auris Medical Holding AG (EARS) & Kura Oncology (KURA)Reviewing Auris Medical Holding AG (EARS) & Kura Oncology (KURA)
www.americanbankingnews.com - August 10 at 4:32 PM
Leerink Swann Analysts Lift Earnings Estimates for Kura Oncology, Inc. (NASDAQ:KURA)Leerink Swann Analysts Lift Earnings Estimates for Kura Oncology, Inc. (NASDAQ:KURA)
www.americanbankingnews.com - August 10 at 7:06 AM
Oppenheimer Holdings Analysts Cut Earnings Estimates for Kura Oncology, Inc. (NASDAQ:KURA)Oppenheimer Holdings Analysts Cut Earnings Estimates for Kura Oncology, Inc. (NASDAQ:KURA)
www.americanbankingnews.com - August 10 at 7:06 AM
Kura Oncology Announces Commencement of Public Offering of Common StockKura Oncology Announces Commencement of Public Offering of Common Stock
finance.yahoo.com - August 10 at 1:20 AM
FY2020 EPS Estimates for Kura Oncology, Inc. (NASDAQ:KURA) Lowered by AnalystFY2020 EPS Estimates for Kura Oncology, Inc. (NASDAQ:KURA) Lowered by Analyst
www.americanbankingnews.com - August 9 at 3:02 PM
Kura Oncology, Inc. (KURA) Issues Quarterly  Earnings ResultsKura Oncology, Inc. (KURA) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 11:14 AM
Kura Oncology, Inc. (NASDAQ:KURA) PT Set at $13.00 by Citigroup Inc.Kura Oncology, Inc. (NASDAQ:KURA) PT Set at $13.00 by Citigroup Inc.
www.americanbankingnews.com - August 8 at 10:06 AM
Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 StudyKura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study
finance.yahoo.com - August 7 at 7:46 PM
Kura Oncology to Report Second Quarter 2017 Financial ResultsKura Oncology to Report Second Quarter 2017 Financial Results
finance.yahoo.com - July 31 at 7:42 PM
FY2017 EPS Estimates for Kura Oncology, Inc. (KURA) Cut by AnalystFY2017 EPS Estimates for Kura Oncology, Inc. (KURA) Cut by Analyst
www.americanbankingnews.com - July 20 at 10:06 AM

Social Media

Financials

Chart

Kura Oncology (NASDAQ KURA) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.